Rezolute (RZLT) EBIT (2012 - 2026)
Rezolute recorded quarterly EBIT of -$17.4 million in Q1 2026, up 28.3% quarter-over-quarter from -$24.2 million in Q4 2025, and up 13.27% year-over-year from -$15.3 million in Q1 2025.
Rezolute's EBIT history runs 15 years deep, the most recent figure standing at -$17.4 million for Q1 2026.
- In Q1 2026, EBIT rose 13.27% year-over-year to -$17.4 million; the TTM figure through Mar 2026 stood at -$87.3 million (down 13.1% YoY), while the FY2025 annual figure was -$79.9 million, down 13.45% from the prior year.
- EBIT came in at -$17.4 million for Q1 2026 at Rezolute, up from -$24.2 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$10.2 million in Q3 2022 to a low of -$25.8 million in Q2 2025.
- A 5-year average of -$17.0 million and a median of -$16.9 million in 2024 frame the typical range for EBIT.
- Across the five-year window, EBIT tumbled 96.13% in 2022 and advanced 13.27% in 2026, its largest moves.
- Rezolute's EBIT stood at -$14.4 million in 2022, then dropped by 5.57% to -$15.2 million in 2023, then slipped by 12.41% to -$17.1 million in 2024, then plunged by 41.81% to -$24.2 million in 2025, then grew by 28.3% to -$17.4 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$17.4 million, -$24.2 million, and -$19.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | -17.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.37 Mn |
| Dec 31, 2025 | -24.22 Mn |
| Sep 30, 2025 | -19.82 Mn |
| Jun 30, 2025 | -25.85 Mn |
| Mar 31, 2025 | -20.02 Mn |
| Dec 31, 2024 | -17.08 Mn |
| Sep 30, 2024 | -16.94 Mn |
| Jun 30, 2024 | -23.10 Mn |
| Mar 31, 2024 | -16.21 Mn |
| Dec 31, 2023 | -15.19 Mn |
| Sep 30, 2023 | -15.91 Mn |
| Jun 30, 2023 | -14.24 Mn |
| Mar 31, 2023 | -17.14 Mn |
| Dec 31, 2022 | -14.39 Mn |
| Sep 30, 2022 | -10.22 Mn |
| Jun 30, 2022 | -11.30 Mn |
| Mar 31, 2022 | -10.75 Mn |
| Dec 31, 2021 | -12.15 Mn |
| Sep 30, 2021 | -7.64 Mn |
| Jun 30, 2021 | -6.64 Mn |
| Mar 31, 2021 | -5.48 Mn |
| Dec 31, 2020 | -7.15 Mn |
| Sep 30, 2020 | -3.62 Mn |
| Jun 30, 2020 | -3.55 Mn |
| Mar 31, 2020 | -5.07 Mn |
| Dec 31, 2019 | -6.72 Mn |
| Sep 30, 2019 | -5.18 Mn |
| Jun 30, 2019 | -3.18 Mn |
| Mar 31, 2019 | -17.04 Mn |
| Dec 31, 2018 | -3.16 Mn |
| Sep 30, 2018 | -2.56 Mn |
| Jun 30, 2018 | -11.31 Mn |
| Mar 31, 2018 | -4.95 Mn |
| Dec 31, 2017 | -5.75 Mn |
| Sep 30, 2017 | -6.72 Mn |
| Jun 30, 2017 | -6.22 Mn |
| Mar 31, 2017 | -5.39 Mn |
| Dec 31, 2016 | -4.89 Mn |
| Sep 30, 2016 | -3.82 Mn |
| Jun 30, 2016 | -3.87 Mn |
| Mar 31, 2016 | -3.72 Mn |
| Dec 31, 2015 | -4.07 Mn |
| Sep 30, 2015 | -3.30 Mn |
| Jun 30, 2015 | -3.09 Mn |
| Mar 31, 2015 | -2.30 Mn |
| Dec 31, 2014 | -3.07 Mn |
| Sep 30, 2014 | -2.24 Mn |
| Jun 30, 2014 | -2.23 Mn |
| Mar 31, 2014 | -1.60 Mn |
| Dec 31, 2013 | -650,118.00 |
| Sep 30, 2013 | -700,903.00 |
| Jun 30, 2013 | -1.01 Mn |
| Mar 31, 2013 | -4.05 Mn |
| Dec 31, 2012 | -500,065.00 |
| Sep 30, 2012 | -542,882.00 |
| Jun 30, 2012 | -227,901.00 |
| Mar 31, 2012 | -94,596.00 |